Impact of Discharge Planning Decision Support on 30 and 60 Day Readmissions

K. Bowles,D. Holland,S. Potashnik,M. Topaz,A. Hanlon

Abstract:

What problem does this paper attempt to address?

Polypharmacy Management in Older Patients

Robert William Hoel,Ryan M Giddings Connolly,Paul Y Takahashi,Ryan M. Giddings Connolly,Paul Y. Takahashi

DOI: https://doi.org/10.1016/j.mayocp.2020.06.012

IF: 11.104

2021-01-01

Mayo Clinic Proceedings

Abstract:<p>Medications to treat disease and extend life in our patients often amass in quantities, resulting in what has been termed "polypharmacy." This imprecise label usually describes the accumulation of 5, and often more, medications. Polypharmacy in advancing age frequently results in drug therapy problems related to interactions, drug toxicity, falls with injury, delirium, and nonadherence. Polypharmacy is associated with resulting increased hospitalizations and higher costs of care for individuals and health care systems. To reduce polypharmacy, we delineate a systematic, consultative approach to identify highest-risk medications and drug-therapy problems. We address strategic reductions (deprescribing) of medications in palliative care, long-term care, and ambulatory older adults. Best practices for reducing opioids, benzodiazepines, and other high-risk medications include education about risk and agreement by patients and their families, advocates, and care teams. Addressing deprescribing should be within the framework of patients' health status as their care and goals transition from longevity to a plan of maintaining alertness, comfort, and satisfaction of quality of life. A team approach to address polypharmacy and avoidance of high-risk therapy is optimal within long-term care. Patients with terminal illnesses or those moving toward a comfort-care emphasis benefit from medication adjustments that are recognized beneficially within each patient's care goals. In caring for older adults, the acknowledgement that complicated regimens and high-risk medications requires a care plan to reduce or prevent medication-related problems and costs that are associated with polypharmacy.</p>

medicine, general & internal
Deprescribing for Older Adults in the Community:Recent Developments and Implications for China

XU Yuanyuan,XU Zhijie,NI Yating,LIANG Xujian,HU Xueting,FANG Zheming,ZHU Yue,FANG Lizheng

DOI: https://doi.org/10.12114/j.issn.1007-9572.2022.0160

2022-01-01

Chinese General Practice

Abstract:It is a great challenge to ensure medication safety in healthcare for older adults, since polypharmacy in this group may increase the risk of potentially inappropriate medications, leading to adverse drug reactions, drug-drug interactions, hospitalizations, increased medical costs, and even deaths. Deprescribing improves patient prognosis and reduces adverse drug events through patient participation, and shared decision-making. The prevalence of multimorbidity and polypharmacy in older adults is notably in community care, the frontline for the management of use of multiple drugs. As primary care physicians have a deep understanding of patients' past and current diagnoses and treatments, they play a vital role in reviewing and managing patients' medications. However, there are few reports on deprescribing in primary care in China. We described the definition of deprescribing, and reviewed its recent advances, with a focus on the implementation process of deprescribing in the community, and the impact of deprescribing on chronic disease management by primary care physicians. This review may provide a reference for further study and policy making regarding deprescribing in the community in China.
Clinical Management of Polypharmacy in the Elderly Population

Bahram Badri,Stephen Stacey,Brianna Konwinski

DOI: https://doi.org/10.33181/13102

2023-08-31

Osteopathic Family Physician

Abstract:Polypharmacy is defined as use of multiple medications (>5) and is common in the elderly adult population. Polypharmacy typically results from the accumulation of treatments for chronic medical conditions such as hypertension, diabetes, coronary artery disease, and psychiatric illnesses. It is associated with problems such as increased risk of falls and adverse medication events. Elderly patients take an average of two to nine medicines per day, and prevalence of polypharmacy in the elderly is 11.5%–62.5%. Elderly patients are at higher risk of adverse drug reactions due to metabolic changes and reduced drug clearance. Evaluation of polypharmacy is an important part of clinical assessment of the elderly population. This process involves performing an adequate medication reconciliation, including supplements, followed by systematic evaluation of medications looking for benefits and harms. It then involves discussing goals of care with the patient and, if necessary, creating a deprescribing plan. Whenprescribing new medications, prescribers should consider starting at the lower end of the dosing range and increasing only after monitoring for benefits and harms.
Issues and challenges of polypharmacy in the elderly: A review of contemporary Indian literature

Abhik Sinha,Shatavisa Mukherjee,Santanu Tripathi,Shanta Dutta

DOI: https://doi.org/10.4103/jfmpc.jfmpc_2581_20

2021-01-01

Journal of Family Medicine and Primary Care

Abstract:The aging population is of growing concern all across the globe as well as in India. Polypharmacy has been defined as the simultaneous use of multiple medications by an individual and the clinical suitability of such use. Polypharmacy is found more frequently in the geriatric population. Researches in India have also reiterated the fact. Polypharmacy in the geriatric population leads to many negative consequences such as increased adverse drug reactions, falls, frailty, and even increased mortality. Moreover, it leads to increased out-of-pocket expenditure. Polypharmacy also poses risk of poor treatment adherence and missed dose in the geriatric population. Mitigation measures in this regard may include increased awareness among physicians, improved medication management and adherence, efforts to reduce self-medication, and improper crosspathy.
Navigating the perils of polypharmacy: A clinical pharmacology case study from elderly patient care

Shambo Samrat Samajdar,Sougata Sarkar,Shravan Venkatraman,Amit Kumar Dey,Banshi Saboo,Shashank R. Joshi

DOI: https://doi.org/10.4103/njpt.njpt_34_24

2024-05-01

Abstract:Abstract: Polypharmacy is increasingly prevalent among elderly populations due to multimorbidity and the expansion of pharmaceutical options. This case report explores the adverse effects of polypharmacy in an elderly patient, emphasizing the importance of appropriate medication management and the role of clinical pharmacologists. A 78-year-old male with multiple comorbidities was discharged with a complex medication regimen from a hospital in West Bengal. Within 5 days, he experienced severe complications including QT prolongation and a significant fall resulting in a femur fracture. These events were precipitated by the interactions among multiple prescribed medications and a previously unreported use of a fixed-dose combination of paroxetine and clonazepam. The case underscores the dangers of polypharmacy, particularly the risk of adverse drug reactions such as QT prolongation and potential torsades de pointes, exacerbated by drug-drug interactions and electrolyte imbalances. It highlights the necessity of comprehensive medication reconciliation and the critical role of clinical pharmacologists in managing complex medication regimens. This case advocates for the integration of clinical pharmacologists into health-care settings to enhance medication safety and efficacy, particularly in elderly patients with polypharmacy. The involvement of pharmacologically trained professionals can significantly mitigate medication-related risks and improve patient outcomes.
Diseases Linked to Polypharmacy in Elderly Patients

Ioannis Vrettos,Panagiota Voukelatou,Apostolos Katsoras,Despoina Theotoka,Andreas Kalliakmanis

DOI: https://doi.org/10.1155/2017/4276047

2017-01-01

Current Gerontology and Geriatrics Research

Abstract:Introduction . Polypharmacy in several cases is deemed necessary and elderly patients are prone to this phenomenon. The objective of this study was to identify the prevalence and the predictors of polypharmacy among consecutively unplanned admissions of patients aged ≥65 years. Patients and Methods . In 310 patients (51% women), mean age 80.24 years (95% CI 79.35–81.10), demographic characteristics, medical history, medications, and cause of admission were recorded. Parametric tests and multiple logistic regression analysis were applied to identify the factors that have significant association with polypharmacy. Results . 53.5% of patients belonged to polypharmacy group. In multivariate analysis the independent predictors of polypharmacy were arterial hypertension ( p = 0.003 , OR = 2.708, and 95% CI 1.400–5.238), coronary artery disease ( p = 0.001 , OR = 8.274, and 95% CI 3.161–21.656), heart failure ( p = 0.030 , OR = 4.042, and 95% CI 1.145–14.270), atrial fibrillation ( p = 0.031 , OR = 2.477, and 95% CI 1.086–5.648), diabetes mellitus ( p = 0.010 , OR = 2.390, and 95% CI 1.232–4.636), dementia ( p = 0.001 , OR = 4.637, and 95% CI 1.876–11.464), and COPD ( p = 0.022 , OR = 3.626, and 95% CI 1.208–10.891). Conclusions . Polypharmacy mainly was linked to cardiovascular diseases. If deprescribing is not feasible, physicians must oversee those patients in order to recognise early, possible drug reactions.

English Else
The Critical Role of Community Geriatricians and Pharmacists in Deprescribing

Daniel Dinarvand,Johann Panthakey,Amirmohammad Heidari,Ahmed Hassan,Mohamed H. Ahmed

DOI: https://doi.org/10.3390/jpm14090924

IF: 3.5083

2024-09-02

Journal of Personalized Medicine

Abstract:Background: Frailty is a clinical syndrome prevalent among the elderly, characterised by a decline in physiological reserves and increased susceptibility to stressors, resulting in higher morbidity and mortality. Diabetes and hypertension are common in frail older individuals, often leading to polypharmacy. In this narrative review, we aimed to evaluate the relationship between frailty, diabetes, and hypertension and to identify effective management strategies and future research directions. Methods: This narrative review was conducted using the Scopus, Medline, PubMed, Cochrane Library, and Google Scholar databases. Results: Frailty significantly impacts the management and prognosis of diabetes and hypertension, which, in turn, affects the progression of frailty. Managing these conditions often involves multiple drugs to achieve strict glycaemic control and blood pressure targets, leading to polypharmacy and associated morbidities, including orthostatic hypotension, falls, fractures, hypoglycaemia, and reduced medication adherence. Identifying frailty and implementing strategies like deprescribing can mitigate the adverse effects of polypharmacy and improve outcomes and quality of life. Despite the availability of effective tools for identifying frailty, many frail individuals continue to be exposed to complex treatment regimens for diabetes and hypertension, leading to increased hospital admissions, morbidity, and mortality. Conclusions: Managing diabetes and hypertension in the frail ageing population requires a multidisciplinary approach involving hospital and community geriatricians and pharmacists. This is important due to the lack of sufficient clinical trials dedicated to diabetes and hypertension in the context of frailty. Future large population studies are needed to assess the best approaches for managing diabetes and hypertension in frail individuals.

medicine, general & internal,health care sciences & services
Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach

Smrithi Sukumar,Ariela R Orkaby,Janice B Schwartz,Zachary Marcum,James L Januzzi,Muthiah Vaduganathan,Haider J Warraich

DOI: https://doi.org/10.1007/s11897-022-00559-w

Abstract:Purpose of review: We provide a review of considerations when applying principles of optimal pharmacotherapy to older adults with heart failure (HF), an analysis on the pivotal clinical trials focusing on applicability to older adults, and multi-disciplinary strategies to optimize the health of HF patients with polypharmacy. Recent findings: Polypharmacy is very common among patients with HF, due to medications for both HF and non-HF comorbidities. Definitions of polypharmacy were not developed specifically for older adults with HF and may need to be modified in order to meaningfully describe medication burden and promote appropriate medical therapy. This is because clinical practice guidelines for multi-drug HF regimens have unique considerations, given that they improve outcomes and symptoms of HF. Adults older than 65 years are well represented in contemporary clinical trials for HF with preserved ejection fraction (HFpEF) and guideline directed medical therapy (GDMT) for HF with reduced ejection fraction (HFrEF). While these trials did not have significant heterogeneity in safety or efficacy across a broad age spectrum, some may have limited representation of adults ≥ 80 years old, the sickest older adults, or those with decreased functional status. There is also a lack of data on the safety and efficacy of deprescribing HF medications, and deprescription in otherwise stable patients may lead to clinical destabilization or disease progression. There is therefore innate tension between the well-studied benefits of optimized HF therapy for older adults that must be weighed against the risks of polypharmacy and many unknowns that still exist. Given the strong evidence that optimized HF therapies confer symptomatic and mortality benefits for older adults, it is clear that polypharmacy in this context can be appropriate. A shift in paradigm is therefore needed when evaluating polypharmacy in patients with HF. Instead of assuming all polypharmacy is "good" or "bad," we propose a concerted move, using a multidisciplinary approach, to focus on the "appropriateness" of specific medications, in order to optimize HF medical therapy. Clinicians of all specialties caring for complex older adults with HF must consider goals of care, functional status, and new evidence-based therapies, in order to optimize this polypharmacy for older adults.
Relationship between polypharmacy and underprescribing

Mascha A. J. Kuijpers,Rob J. Van Marum,Antoine C. G. Egberts,Paul A. F. Jansen,The OLDY study group,Rob J. van Marum,

DOI: https://doi.org/10.1111/j.1365-2125.2007.02961.x

2008-01-01

British Journal of Clinical Pharmacology

Abstract:AIMS: Underprescribing is increasingly recognized as an important problem. The aim of this study was to determine the relationship between polypharmacy and underprescribing.METHODS: Treatment of current medical problems in geriatric patients was compared with general practitioner and national guidelines. Underprescription was defined as lack of an indicated drug, while no reason could be found for not prescribing it. Polypharmacy was defined as five or more drugs.RESULTS: Polypharmacy was present in 61% of 150 patients. Underprescription was found in 47 (31%). Of patients with polypharmacy 42.9% were undertreated, in contrast to 13.5% of patients using four medicines or less (OR 4.8, 95% CI 2.0, 11.2). The estimated probability of underprescription increased significantly with the number of drugs.CONCLUSIONS: We found a clear relationship between polypharmacy and underprescribing.

pharmacology & pharmacy
Polypharmacy and Deprescribing in Older Adults.

E. McDonald,Wade Thompson

DOI: https://doi.org/10.1146/annurev-med-070822-101947

2023-09-20

Annual Review of Medicine

Abstract:Older adults commonly end up on many medications. Deprescribing is an important part of individualizing care for older adults. It is an opportunity to discuss treatment options and revisit medications that may not have been reassessed in many years. A large evidence base exists in the field, suggesting that deprescribing is feasible and safe, though questions remain about the potential clinical benefits. Deprescribing research faces a myriad of challenges, such as identifying and employing the optimal outcome measures. Further, there is uncertainty about which deprescribing approaches are likely to be most effective and in what contexts. Evidence on barriers and facilitators to deprescribing has underscored how deprescribing in routine clinical practice can be complex and challenging. Thus, finding practical, sustainable ways to implement deprescribing is a priority for future research in the field. Expected final online publication date for the Annual Review of Medicine, Volume 75 is January 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Medicine
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women

Patel, Shreya,Kumar, Manish,Beavers, Craig J.,Karamat, Saad,Alenezi, Fawaz

DOI: https://doi.org/10.1007/s11883-022-01055-1

IF: 5.967

2022-07-21

Current Atherosclerosis Reports

Abstract:The intent of this review is to provide an update in polypharmacy in older adults and women with a focus on common determinants and strategies to mitigate polypharmacy. Polypharmacy is becoming a critical focus in the management of cardiovascular diseases. It may emerge unintentionally while managing multimorbidity in older adults or in the vulnerable subgroup of patients, such as pregnant and lactating females. Clinicians should utilize several approaches such as deprescribing, sex-specific risk assessment, and encouraging healthy lifestyle to minimize inappropriate and unnecessary use of medications. A shared decision-making model along with coordination and collaboration among healthcare providers should be utilized in the selection and management of pharmacotherapies.

peripheral vascular disease
Drug Utilisation Review among Geriatric Patients with Noncommunicable Diseases in a Primary Care Setting in Malaysia

Priya Manirajan,Palanisamy Sivanandy

DOI: https://doi.org/10.3390/healthcare11121665

2023-06-06

Health Care

Abstract:A prospective cross-sectional study was conducted to analyse the drugs prescribed to the elderly population with noncommunicable diseases and to determine the polypharmacy at a primary care clinic in Negeri Sembilan, Malaysia. The study was conducted for 6 months at the primary care clinic of Gemas. Geriatric patients above the age of 65 and diagnosed with noncommunicable diseases were included upon providing written informed consent. The majority of the geriatric patients were between 65 and 69 years (mean: 69.72 ± 2.85) and prescribed 4 or more medications (mean: 5.18 ± 0.64, p = 0.007). More than 95% (n = 295) of the geriatrics were found to have multimorbidity, in which around 45% (n = 139) had type-2 diabetes together with hypertension and dyslipidaemia. Combination therapy was prescribed to more than 97% (n = 302) of the elderly, whereas cardiovascular and endocrine medications were the most commonly prescribed. Ten prescriptions were found to have drug-related problems, prescribing cascade (80%), lack of medicine optimisation (10%), and inappropriate prescription (10%). In this study, the majority of the elderly had multimorbidity; polypharmacy was commonly seen among geriatric patients. Polypharmacy is the biggest threat to the elderly population, as it increases the chances of falls and fall-related injuries. Medicine optimisation and deprescribing will reduce the chances of drug-related problems and morbidity and mortality associated with polypharmacy and over-consumption of medications. Hence, the study recommends the health fraternity look for medication optimisation and deprescribing to reduce the future complications associated with polypharmacy.

health care sciences & services,health policy & services
A STUDY ON POLYPHARMACY AMONG ELDERLY PATIENTS IN MEDICINE WARD OF A TERTIARY CARE TEACHING HOSPITAL OF EASTERN INDIA

Abhishek Ghosh,Shankar Dey,Madhura Banerjee,Soham Dutta

DOI: https://doi.org/10.36106/ijar/7101510

2022-11-01

Indian Journal Of Applied Research

Abstract:Background: In the modern era, with the increase in the lifespan of individuals with increasing access to health-care facilities, the population of elderly is also increasing with an equal pace. However, on the other hand, with the increasing population of the elderly another important issue of polypharmacy has also emerged. Elderly people usually have more disease conditions for which more of medications are prescribed in older individuals as compared to younger population. Hence, optimizing drug therapy in this aging population is a challenging task for physician. Polypharmacy can also lead to increase in drug interactions, adverse drug reactions, and medication errors. It was an observational, cross-sectional, prospective study. The Materials and Methods: study was conducted in patients admitted in general medicine wards at College of Medicine& JNM Hospital, Kalyani, West Bengal. The study involved 320 elderly patients (above 65 years of age) of either sex for 3 months from January to March 2020. The information recorded included the demographic details of the patients, diagnosis, comorbid illnesses, details about medications being, the total number of drugs being used, and the factors associated with polypharmacy. A total of 320 geriatric patients were included in the study. Pol Results: ypharmacy was found (>5 medications/day) in 79.71% of geriatrics. Pantoprazole , antimnicrobials and NSAIDS were most commonly prescribed drugs. To counteract the problems Conclusion: associated with polypharmacy, regular follow- ups and proper monitoring of drug regimens of older individuals are the need of the hour.
The prevalence of polypharmacy in older Europeans: A multi‐national database study of general practitioner prescribing

Marion Bennie,Yared Santa‐Ana‐Tellez,Githa Fungie Galistiani,Julien Trehony,Johanna Despres,Laurence Sophie Jouaville,Elisabetta Poluzzi,Lucas Morin,Ingrid Schubert,Seán MacBride‐Stewart,Monique Elseviers,Paola Nasuti,Katja Taxis

DOI: https://doi.org/10.1111/bcp.16113

2024-05-31

British Journal of Clinical Pharmacology

Abstract:Aims The aims of this study were to measure the prevalence of polypharmacy and describe the prescribing of selected medications known for overuse in older people with polypharmacy in primary care. Methods This was a multinational retrospective cohort study across six countries: Belgium, France, Germany, Italy, Spain and the UK. We used anonymized longitudinal patient‐level information from general practice databases hosted by IQVIA. Patients ≥65 years were included. Polypharmacy was defined as having 5–9 and ≥10 distinct drug classes (ATC Level 3) prescribed during a 6‐month period. Selected medications were: opioids, antipsychotics, proton pump inhibitors (PPI), benzodiazepines (ATC Level 5). We included country experts on the healthcare context to interpret findings. Results Age and gender distribution was similar across the six countries (mean age 75–76 years; 54–56% female). The prevalence of polypharmacy of 5–9 drugs was 22.8% (UK) to 58.3% (Germany); ≥10 drugs from 11.3% (UK) to 28.5% (Germany). In the polypharmacy population prescribed ≥5 drugs, opioid prescribing ranged from 11.5% (France) to 27.5% (Spain). Prescribing of PPI was highest with almost half of patients receiving a PPI, 42.3% (Germany) to 65.5% (Spain). Benzodiazepine prescribing showed a marked variation between countries, 2.7% (UK) to 34.9% (Spain). The healthcare context information explained possible underreporting for selected medications. Conclusions We have found a high prevalence of polypharmacy with more than half of the older population being prescribed ≥5 drugs in four of the six countries. Whilst polypharmacy may be appropriate in many patients, worryingly high usage of PPIs and benzodiazepines supports current efforts to improve polypharmacy management across Europe.

pharmacology & pharmacy
Polypharmacy With Common Diseases in Hospitalized Elderly Patients

Fumihiro Mizokami,Yumiko Koide,Takeshi Noro,Katsunori Furuta

DOI: https://doi.org/10.1016/j.amjopharm.2012.02.003

2012-04-01

The American Journal of Geriatric Pharmacotherapy

Abstract:BACKGROUND: Elderly persons are exposed to polypharmacy because of multiple chronic conditions. Many risk factors for polypharmacy have been identified including age, race/ethnicity, sex, educational achievement level, health status, and number of chronic diseases. However, drugs prescribed for individual diseases have not been analyzed.OBJECTIVE: The objective of this study was to analyze each common disease in the elderly with respect to prescribed drugs and polypharmacy.METHODS: A 1-year (January through December 2009) cross-sectional study was performed in which all drugs given to hospitalized elderly patients (age, >65 years) were investigated. Common diseases of the elderly were separated into disease groups including hypertension, hyperlipidemia, gastric ulcer, previous stroke, reflux esophagitis, diabetes mellitus, malignancy, osteoporosis, angina pectoris, congestive heart failure, chronic obstructive pulmonary disease, dementia, and depression.RESULTS: Among 1768 elderly patients, the mean (range) age of study patients was 78 (65 to 100) years. The mean (SD) number of diseases was 7.7 (3.4), and the number of drugs overall was 4.9 (3.6). The number of drugs and prevalence of polypharmacy were hypertension, 5.2 (3.9 [51%]); hyperlipidemia, 5.6 (3.8 [58%]); gastric ulcer, 5.4 (3.8 [53%]); previous stroke, 5.8 (3.2 [61%]); reflux esophagitis, 5.6 (3.8 [40%]), diabetes mellitus, 5.6 (3.1 [54%]); malignancy, 4.1 (3.1 [37%]); osteoporosis, 5.4 (3.4 [45%]); angina pectoris, 5.7 (3.6 [42%]); congestive heart failure, 6.1 (4.0 [60%]); chronic obstructive pulmonary disease, 5.0 (3.5 [53%]); dementia, 5.1 (3.2 [52%]); and depression, 7.0 (4.2 [73%]).CONCLUSIONS: When assessing the risk of polypharmacy, physicians should carefully consider the type of any chronic disease. Elderly patients with multiple diseases may be subjected to further polypharmacy.

English Else
The Role of Deprescribing in Older Adults with Chronic Kidney Disease

Laura K. Triantafylidis,Chelsea E. Hawley,Laura P. Perry,Julie M. Paik

DOI: https://doi.org/10.1007/s40266-018-0593-8

2018-10-04

Abstract:Older adults with chronic kidney disease (CKD) often experience polypharmacy, a recognized predictor of prescribing problems including inappropriately dosed medications, drug–drug and drug–disease interactions, morbidity and mortality. Polypharmacy is also associated with nonadherence, which leads to recurrent hospitalizations and poorer hemodialysis outcomes in CKD patients. Further complicating medication management in this vulnerable population are the physiologic changes that occur with both age and CKD. This guide for pharmacists and prescribers offers considerations in medication evaluation and management among older adults with CKD. Careful prescribing with the aid of tools such as the American Geriatrics Society Beers Criteria can support safe medication use and appropriate prescribing. Polypharmacy may be systematically addressed through ‘deprescribing,’ an evidence-based process that enables identification and elimination of unnecessary or inappropriate medications. Detailed guidance for deprescribing in older adults with CKD has not been published previously. We highlight three specific targets for medication optimization and deprescribing in older adults with CKD: (1) proton pump inhibitors, (2) oral hypoglycemic agents, including newer classes of agents, and (3) statins. These medication classes have been chosen as they represent three of the most commonly prescribed classes of medications in the United States. For each area, we review considerations for medication use in older adults with CKD and provide strategies to avoid, modify, or discontinue these medications when clinically indicated. By utilizing deprescribing techniques, pharmacists are well positioned to help decrease the medication burden in older adults with CKD, thereby potentially reducing the risk of morbidity and mortality associated with polypharmacy.

pharmacology & pharmacy,geriatrics & gerontology,gerontology
Irrational polypharmacy and potentially inappropriate medications in patients with dementia: Treatment strategies

M. Štuhec,EPA2023SP-1103,

DOI: https://doi.org/10.1192/j.eurpsy.2023.105

2023-03-01

European Psychiatry

Abstract:Abstract Most patients with dementia are treated with irrational polypharmacy, which leads to higher mortality and other negative consequences (higher costs). Nearly 50% of elderly patients take one or more medications that are not medically necessary, which represents another important aspect of medication optimization. Research has established a strong relationship between irrational polypharmacy and its negative clinical consequences, including a negative impact on dementia, especially in patients with excessive polypharmacy (10 or more medications). These patients are underrepresented in the treatment guidelines and randomized controlled trials, although they represent a substantial patient population. The burden of irrational polypharmacy has also been associated with a greater risk of adverse drug events, drug-drug interactions, medication non-adherence and a higher risk of potentially inappropriate medication (PIM) use. Different treatment strategies have been available to reduce irrational polypharmacy in this population. The best intervention for irrational polypharmacy reduction in this population involves an inter-professional approach (collaborative care approach) that often includes special tools, a basic pharmacological approach and collaboration with a clinical pharmacist. Disclosure of Interest None Declared

psychiatry
Polypharmacy in Older Adults Hospitalized for Heart Failure

Ozan Unlu,Emily B. Levitan,Evgeniya Reshetnyak,Jerard Kneifati-Hayek,Ivan Diaz,Alexi Archambault,Ligong Chen,Joseph T. Hanlon,Mathew S. Maurer,Monika M. Safford,Mark S. Lachs,Parag Goyal

DOI: https://doi.org/10.1161/circheartfailure.120.006977

2020-01-01

Circulation Heart Failure

Abstract:Background: Despite potential harm that can result from polypharmacy, real-world data on polypharmacy in the setting of heart failure (HF) are limited. We sought to address this knowledge gap by studying older adults hospitalized for HF derived from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke). Methods: We examined 558 older adults aged ≥65 years with adjudicated HF hospitalizations from 380 hospitals across the United States. We collected and examined data from the REGARDS baseline assessment, medical charts from HF-adjudicated hospitalizations, the American Hospital Association annual survey database, and Medicare’s Hospital Compare website. We counted the number of medications taken at hospital admission and discharge; and classified each medication as HF-related, non-HF cardiovascular-related, or noncardiovascular-related. Results: The vast majority of participants (84% at admission and 95% at discharge) took ≥5 medications; and 42% at admission and 55% at discharge took ≥10 medications. The prevalence of taking ≥10 medications (polypharmacy) increased over the study period. As the number of total medications increased, the number of noncardiovascular medications increased more rapidly than the number of HF-related or non-HF cardiovascular medications. Conclusions: Defining polypharmacy as taking ≥10 medications might be more ideal in the HF population as most patients already take ≥5 medications. Polypharmacy is common both at admission and hospital discharge, and its prevalence is rising over time. The majority of medications taken by older adults with HF are noncardiovascular medications. There is a need to develop strategies that can mitigate the negative effects of polypharmacy among older adults with HF.
Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments

Derek Stewart,Alpana Mair,Martin Wilson,Przemyslaw Kardas,Pawel Lewek,Albert Alonso,Jennifer McIntosh,Katie MacLure,SIMPATHY consortium

DOI: https://doi.org/10.1080/14740338.2017.1265503

2016-11-25

Expert Opinion on Drug Safety

Abstract:INTRODUCTION: Single disease state led evidence-based guidelines do not provide sufficient coverage of issues of multimorbidities, with the cumulative impact of recommendations often resulting in overwhelming medicines burden. Inappropriate polypharmacy increases the likelihood of adverse drug events, drug interactions and non-adherence. Areas covered: A detailed description of a pan-European initiative, 'Stimulating Innovation Management of Polypharmacy and Adherence in the Elderly, SIMPATHY', which is a project funded by the European Commission to support innovation across the European Union. This includes a systematic review of the literature aiming to summarize and review critically current policies and guidelines on polypharmacy management in older people. The policy driven, evidence-based approach to managing inappropriate polypharmacy in Scotland is described, with consideration of a change management strategy based on Kotter's eight step process for leading sustainable change. Expert opinion: The challenges around promoting appropriate polypharmacy are on many levels, primarily clinical, organisational and political, all of which any workable solution will need to address. To be effective, safe and efficient, any programme that attempts to deal with the complexities of prescribing in this population must be patient-centred, clinically robust, multidisciplinary and designed to fit into the healthcare system in which it is delivered.

pharmacology & pharmacy
Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia

H H Stassen,S Bachmann,R Bridler,K Cattapan,D Herzig,A Schneeberger,E Seifritz

DOI: https://doi.org/10.1007/s00406-021-01358-5

Abstract:Current treatment standards in psychiatry are oriented towards polypharmacy, that is, patients receive combinations of several antidepressants, antipsychotics, mood stabilizers, anxiolytics, hypnotics, antihistamines, and anticholinergics, along with other somatic treatments. In tandem with the beneficial effects of psychopharmacological drug treatment, patients experience significant adverse reactions which appear to have become more frequent and more severe with the rise of ubiquitous polypharmacy. In this study, we aimed to assess today's acute inpatient treatment of depressive and schizophrenic disorders with focus on therapeutic strategies, medications, adverse side effects, time course of recovery, and efficacy of treatments. Of particular interest was the weighing of the benefits and drawbacks of polypharmacy regimens. We recruited a total of 320 patients hospitalized at three residential mental health treatment centers with a diagnosis of either schizophrenic (ICD-10: "F2x.x"; n = 94; "F2 patients") or depressive disorders (ICD-10: "F3x.x"; n = 226; "F3 patients"). The study protocol included (1) assessment of previous history by means of the SADS Syndrome Check List SSCL-16 (lifetime version); (2) repeated measurements over 5 weeks assessing the time course of improvement by the Hamilton Depression Scale HAM-D and the Positive and Negative Syndrome Scale PANSS, along with medications and adverse side effects through the Medication and Side Effects Inventory MEDIS; and (3) the collection of blood samples from which DNA and serum were extracted. Polypharmacy was by far the most common treatment regimen (85%) in this study. On average, patients received 4.50 ± 2.68 medications, consisting of 3.30 ± 1.84 psychotropic drugs, plus 0.79 ± 1.13 medications that alleviate adverse side effects, plus 0.41 ± 0.89 other somatic medications. The treating psychiatrists appeared to be the main determining factor in this context, while «previous history» and «severity at baseline» played a minor role, if at all. Adverse drug reactions were found to be an inherent component of polypharmacy and tended to have a 2-3 times higher incidence compared to monotherapy. Severe adverse reactions could not be attributed to a particular drug or drug combination. Rather, the empirical data suggested that severe side effects can be triggered by virtually all combinations of drugs, provided patients have a respective vulnerability. In terms of efficacy, there were no advantages of polypharmacy over monotherapy. The results of this study underlined the fact that polypharmacy regimens are not equally suited for every patient. Specifically, such regimens appeared to have a negative impact on treatment outcome and to obfuscate the "natural" time course of recovery through a multitude of interfering factors. Evidence clearly speaks against starting just every therapeutic intervention in psychiatry with a combination of psychopharmaceuticals. We think that it is time for psychiatry to reconsider its treatment strategies, which are far too one-sidedly fixated on psychopharmacology and pay far too little attention to alternative approaches, especially in mild cases where psychotherapy without concurrent medication should still be an option. Also, regular exercises and sports can definitely be an effective therapeutic means in a considerable number of cases. General practitioners (GPs) are particularly in demand here.

Impact of Discharge Planning Decision Support on 30 and 60 Day Readmissions

Polypharmacy Management in Older Patients

Deprescribing for Older Adults in the Community:Recent Developments and Implications for China

Clinical Management of Polypharmacy in the Elderly Population

Issues and challenges of polypharmacy in the elderly: A review of contemporary Indian literature

Navigating the perils of polypharmacy: A clinical pharmacology case study from elderly patient care

Diseases Linked to Polypharmacy in Elderly Patients

The Critical Role of Community Geriatricians and Pharmacists in Deprescribing

Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach

Relationship between polypharmacy and underprescribing

Polypharmacy and Deprescribing in Older Adults.

Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women

Drug Utilisation Review among Geriatric Patients with Noncommunicable Diseases in a Primary Care Setting in Malaysia

A STUDY ON POLYPHARMACY AMONG ELDERLY PATIENTS IN MEDICINE WARD OF A TERTIARY CARE TEACHING HOSPITAL OF EASTERN INDIA

The prevalence of polypharmacy in older Europeans: A multi‐national database study of general practitioner prescribing

Polypharmacy With Common Diseases in Hospitalized Elderly Patients

The Role of Deprescribing in Older Adults with Chronic Kidney Disease

Irrational polypharmacy and potentially inappropriate medications in patients with dementia: Treatment strategies

Polypharmacy in Older Adults Hospitalized for Heart Failure

Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments

Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia